Actual Medicinal Product (AMP) Myloxifin 10mg/5mg modified-release tablets (Ridge Pharma Ltd)

Stability Information

(Some stability information inherited from generic)

Stability
compatible_special_measures logo Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
Notes

Light sensitive medicine. Store in light resistant container.   Moisture sensitive medicine. Store in airtight (sealed) MCA . Manufacturer recommends storing in original container.
No stability data in MCAs available.

Provenance

This recommendation is based on the products Targinact 10mg/5mg prolonged-release tablets (Napp Pharmaceuticals Limited) and Oxycodone/Naloxone 10mg/5mg prolonged-release tablets (Krka UK Ltd).

Generic
Oxycodone + Naloxone
Formulation
Oxycodone 10mg / Naloxone 5mg modified-release tablets
  • Oxycodone + Naloxone
    • Oxycodone 10mg / Naloxone 5mg modified-release tablets

      • Myloxifin 10mg/5mg modified-release tablets (Ridge Pharma Ltd)